Home-grown drug manufacturer Dabur Pharma has declared that the promoters and certain other stockholders of the company have signed up share purchase deal with Singapore-based Fresenius Kabi Pte Ltd, which is a 100% subsidiary of the $12-billion healthcare major Fresenius SE.

In conformance to the deal Fresenius will acquire about 73.27% of the company’s overall issued plus paid-up equity share capital at Rs 76.50 per equity share.

The deal, subject to necessary regulatory approvals, values Dabur Pharma at Rs 1198.75 crore.

Dabur Pharma is a specialty pharmaceuticals company with a focus on oncology. In the past, Dabur Pharma had taken strategic steps to concentrate on niche business segments. In 2007, the company sold its non-oncology business to Alembic for Rs 159 crore to focus on its oncology segment. In 2003, Dabur had demerged its pharmaceutical division from the FMCG business.

The fully integrated pharmaceutical business of Dabur Pharma covers the oral and injectable finished dosage forms and active pharmaceutical ingredients and intermediates. The company has its manufacturing units for finished dosage forms in Bordon (UK) and Baddi (India), while the active pharmaceutical ingredients (APIs) are manufactured in Kalyani (India) and some products come from Dabur India`s Sahibabad facilities.

Shares of the company declined Rs 3.05, or 4.22%, to end at Rs 69.15. The total volume of shares traded was 74,357 at the BSE. (Thursday)